Puri R - Search Results

1

Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.

Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, Naylor B, Scally AJ, Seargent JM, Shah T, Puri R, Phillips RM. Basu S, et al. Among authors: puri r. Int J Cancer. 2004 May 1;109(5):703-9. doi: 10.1002/ijc.20005. Int J Cancer. 2004. PMID: 14999778

2

Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP.

Phillips RM, Basu S, Brown JE, Flannigan GM, Loadman PM, Martin SW, Naylor B, Puri R, Shah T. Phillips RM, et al. Among authors: puri r. Int J Oncol. 2004 Apr;24(4):1005-10. Int J Oncol. 2004. PMID: 15010841

3

NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.

Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, Naylor B, Puri R, Scally AJ, Seargent JM, Shah T, Phillips RM. Basu S, et al. Among authors: puri r. Int J Oncol. 2004 Oct;25(4):921-7. Int J Oncol. 2004. PMID: 15375541

4

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

Puri R, Palit V, Loadman PM, Flannigan M, Shah T, Choudry GA, Basu S, Double JA, Lenaz G, Chawla S, Beer M, Van Kalken C, de Boer R, Beijnen JH, Twelves CJ, Phillips RM. Puri R, et al. J Urol. 2006 Oct;176(4 Pt 1):1344-8. doi: 10.1016/j.juro.2006.06.047. J Urol. 2006. PMID: 16952628 Clinical Trial.

5

Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists.

Clarke NS, Basu S, Prescott S, Puri R. Clarke NS, et al. Among authors: puri r. BJU Int. 2006 Apr;97(4):716-9. doi: 10.1111/j.1464-410X.2006.05970.x. BJU Int. 2006. PMID: 16536760

6

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R. Jain A, et al. Among authors: puri r. Urology. 2009 May;73(5):1083-6. doi: 10.1016/j.urology.2007.12.062. Epub 2009 Feb 20. Urology. 2009. PMID: 19232688

7

Expression of HIF-1alpha and Glut-1 in human bladder cancer.

Palit V, Phillips RM, Puri R, Shah T, Bibby MC. Palit V, et al. Among authors: puri r. Oncol Rep. 2005 Oct;14(4):909-13. doi: 10.3892/or.14.4.909. Oncol Rep. 2005. PMID: 16142350

8

Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.

Palit V, Shah T, Biyani CS, Elmasry Y, Sarkar R, Flannigan GM, Puri R. Palit V, et al. Among authors: puri r. Int Urol Nephrol. 2005;37(3):507-10. doi: 10.1007/s11255-004-4709-1. Int Urol Nephrol. 2005. PMID: 16307331

9

Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.

Shah T, Palit V, Biyani S, Elmasry Y, Puri R, Flannigan GM. Shah T, et al. Among authors: puri r. Eur Urol. 2002 Oct;42(4):329-32; discussion 332. doi: 10.1016/s0302-2838(02)00319-6. Eur Urol. 2002. PMID: 12361896 Clinical Trial.

10

Obtaining archived pathological material for biomedical research.

Basu S, Martin SW, Phillips RM, Puri R. Basu S, et al. Among authors: puri r. Lancet. 2003 Apr 19;361(9366):1394. doi: 10.1016/s0140-6736(03)13069-3. Lancet. 2003. PMID: 12711507 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,401 results

Search Page

Filters